TXG · NASDAQ
10x Genomics (TXG) Stock Price & Fundamentals
10x Genomics (TXG) closed at $301.24 on Oct 9, 2026, up 0.43% from the previous close of $299.95.
Share price, past year
1Y −19.26%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $301.24 |
| Sep 30, 2026 | $303.30 |
| Aug 31, 2026 | $313.54 |
| Jul 31, 2026 | $333.15 |
| Jun 30, 2026 | $333.92 |
| May 29, 2026 | $345.32 |
| Apr 30, 2026 | $356.19 |
| Mar 31, 2026 | $348.63 |
| Feb 27, 2026 | $364.99 |
| Jan 30, 2026 | $385.17 |
| Dec 31, 2025 | $397.80 |
| Nov 28, 2025 | $391.54 |
| Oct 31, 2025 | $403.94 |
Key statistics
- Market cap
- $38.47B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.59
- Revenue (TTM)
- $616.91M
- Net income (TTM)
- −$75.13M
- Shares outstanding
- 127.7M
- Dividend yield
- —
- 52-week range
- $296.35 – $419.53
10x Genomics's market cap is $38.47B, based on a share price of $301.24 and 127.7M shares outstanding as of Dec 31, 2025.
Financials
10x Genomics reported revenue of $642.82M for fiscal 2025, up 5.25% from fiscal 2024.
10x Genomics reported a net loss of $43.54M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 9 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $642.82M | +5.3% | −$43.54M | −6.8% | −$0.35 | $130.12M |
| FY2024ended Dec 31, 2024 | $610.79M | −1.3% | −$182.63M | −29.9% | −$1.52 | −$5.73M |
| FY2023ended Dec 31, 2023 | $618.73M | +19.8% | −$255.10M | −41.2% | −$2.18 | −$63.80M |
| FY2022ended Dec 31, 2022 | $516.41M | +5.3% | −$166.00M | −32.2% | −$1.46 | −$165.27M |
| FY2021ended Dec 31, 2021 | $490.49M | +64.1% | −$58.22M | −11.9% | −$0.53 | −$122.65M |
| FY2020ended Dec 31, 2020 | $298.85M | +21.5% | −$542.73M | −181.6% | −$5.37 | −$254.56M |
| FY2019ended Dec 31, 2019 | $245.89M | +68.1% | −$31.25M | −12.7% | −$0.80 | −$8.12M |
| FY2018ended Dec 31, 2018 | $146.31M | +105.8% | −$112.49M | −76.9% | −$8.40 | −$82.69M |
| FY2017ended Dec 31, 2017 | $71.09M | — | −$18.76M | −26.4% | −$1.62 | −$14.46M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $151.04M | −$17.93M | −$0.14 |
| Q1 FY2026ended Mar 31, 2026 | $150.84M | −$13.47M | −$0.10 |
| Q4 FY2025ended Dec 31, 2025 | $166.03M | −$16.25M | −$0.13 |
| Q3 FY2025ended Sep 30, 2025 | $149.00M | −$27.47M | −$0.22 |
| Q2 FY2025ended Jun 30, 2025 | $172.91M | $34.54M | $0.28 |
| Q1 FY2025ended Mar 31, 2025 | $154.88M | −$34.36M | −$0.28 |
| Q4 FY2024ended Dec 31, 2024 | $165.02M | −$49.03M | −$0.40 |
| Q3 FY2024ended Sep 30, 2024 | $151.65M | −$35.75M | −$0.30 |
Company profile
- Name
- 10x Genomics, Inc.
- Ticker
- TXG
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Laboratory Analytical Instruments
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA 94588
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001770787
Recent SEC filings
- Aug 7, 2026
- Aug 6, 2026
- Jun 8, 2026
- May 8, 2026
- May 7, 2026
- Feb 13, 2026
- Feb 12, 2026
- Jan 12, 2026
Frequently asked questions
What is 10x Genomics's stock price?
10x Genomics (TXG) closed at $301.24 on Oct 9, 2026, up 0.43% from the previous close of $299.95.
What is 10x Genomics's market cap?
10x Genomics's market cap is $38.47B, based on a share price of $301.24 and 127.7M shares outstanding as of Dec 31, 2025.
How much revenue does 10x Genomics make?
10x Genomics reported revenue of $642.82M for fiscal 2025, up 5.25% from fiscal 2024.
Does 10x Genomics pay a dividend?
10x Genomics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from 10x Genomics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures